George P Hemstreet, MD, PhD

Professor

Contact

GeorgeHemstreet@creighton.edu
School of Medicine
Department of Urology Fellowships

George P Hemstreet, MD, PhD

Professor

Dr. Hemstreet as a clinician scientist obtained his Ph.D. following his medical training in Microbiology and Immunology. After completing his surgical residency his career developed as a clinical urologist and basic science researcher by utilizing his immunological background as it applied to tumor immunology and infectious disease and later to biophysical cytochemistry. Subsequently his career interests focused on the development of and validation of quantitative fluorescence image analysis for assaying proteins in single cells and more recently to the area of tissues proteomics (zeptomole level with a 15% variance). Early in his career he pioneered the field of molecular epidemiology and biomarkers when he scientific and medical director of Notification and Screening Program for workers exposed to aniline dyes sponsored by Workers Institute and NIOSH. This study contributed to defining the then new discipline of molecular epidemiology. The microscope based fluorescence technique used in this study was automated incorporating fluorescence imaging. This technology was later recognized by the National Research Council where Dr. Hemstreet served as Vice Committee for the committee on Biomarkers in Urinary Toxicology. The two year sojourn spawned the EDRN and served as a basis for increasing the funding for cancer prevention at the NCI. This leadership imitative was preceded by the programming of a fluorescence microscope for single cell proteomics. The sensitivity of this methodology defined alterations in nuclear and cytoplasmic actin depolymerization (G-actin/F-actin ratio) explaining the cardinal single cell signature of malignancy (nuclear cytoplasmic ratio). The instrumentation and the analysis of over 15,000 samples scientifically validated Slaughter”s hypothesis of molecular field disease in bladder cancer biopsy specimens which subsequently was further verified by a large bladder cancer six year longitudinal cohort study in five Chinese provinces. These concepts were vitally important for the integrated conceptual appreciation of biomarkers as it related to defining malignant associated dysplasia’s (Linxien Study) that heralded the malignant cancer phenotype. During these studies Dr. Hemstreet was the founder of a biomedical research company CytoDiagnostics which became the centerpiece and financial backbone for the establishment the Biomedical Research Park Associated with the University of Oklahoma Medical Center. The role of biomarkers for pharmacological monitoring of drug effects on cellular differentiation so key to chemoprevention was introduced. More recently, a method was developed for studying the proteomic changes in the human tissues microenvironment, a concept initially hypothesized in the National Research Council Report.

Teaching Interests

  • Urologic Oncology, Immunology, Biomarkers in Molecular Biology

Department

Urology

Position

Professor

Books

  • Bladder Tumors
    Bishay John H., Intravesical Immunotherapy: BCG [Book Chapter] 2011
  • Advances in Bladder Research
    Hurst Robert E., Complexity, Retinoid-Responsive Gene Networks, and Bladder Carcinogenesis [Book Chapter] 1999
  • Hemstreet George P, Selection and Development of Biomarkers for Bladder Cancer - 3 [Book Chapter] 1998

Publications

  • The Prostate
    Zhou Cindy Ke, Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers
    77:16, p. 1573 - 1582 2017
  • Cancer epidemiology, biomarkers & prevention
    Cook Michael B., Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations
    26:11, p. 1660 - 1666 2017
  • Journal of the National Comprehensive Cancer Network
    Carroll Peter R., NCCN Guidelines Insights: Prostate Cancer Early Detection
    14:5, p. 509 - 519 2016
  • Journal of the National Comprehensive Cancer Network
    Carroll Peter R., Prostate Cancer Early Detection, Version 2.2015 Clinical Practice Guidelines in Oncology
    13:12, p. 1534 - 1561 2015
  • Journal of the National Comprehensive Cancer Network
    Carroll Peter R., Prostate Cancer Early Detection, Version 1.2014
    12:9, p. 1211 - 1219 2014
  • Journal of clinical oncology
    Tandra Pavankumar, Sarcomatoid renal cell carcinoma (SRCC): University of Nebraska Medical Center experience
    31:6_suppl, p. 472 - 472 2013
  • Journal of immunotherapy (1997)
    Hemstreet George P., Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens
    36:1, p. 57 - 65 2013
  • Lasers in medical science
    Kaushik Dharam, Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer
    27:5, p. 1099 - 1102 2012
  • Urology (Ridgewood, N.J.)
    Berglund Ryan K., Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109
    79:3, p. 633 - 637 2012
  • Prostate cancer
    Wang Jue, Younger Age Is an Independent Predictor for Poor Survival in Patients with Signet Ring Prostate Carcinoma
    2011, p. 216169 - 8 2011
  • Studies in health technology and informatics
    Park Eugene S, The initiation of a preoperative and postoperative telemedicine urology clinic
    163, p. 425 - 427 2011
  • International braz j urol : official journal of the Brazilian Society of Urology
    Villanueva Carlos, The approach to the difficult urethral catheterization among urology residents in the United States
    36:6, p. 710 - 5; discussion 715-7 2010
  • Rare tumors
    Wang Jue, Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate
    2:3, p. 130 - 134 2010
  • Journal of the National Comprehensive Cancer Network
    Kawachi Mark H, NCCN clinical practice guidelines in oncology: prostate cancer early detection
    8:2, p. 240 - 262 2010
  • Sarcoma
    Wang Fen Wei, Clinical Features of Sarcomatoid Carcinoma (Carcinosarcoma) of the Urinary Bladder: Analysis of 221 Cases, p. 1 - 7 2010
  • The Journal of urology
    Hemstreet George P., Editorial Comment
    181:2, p. 553 - 553 2009
  • International journal of cancer
    Huang DALI, UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer
    126:2, p. 315 - 327 2009
  • The Journal of urology
    Chen Chung-Hsin, Clinicopathological Characteristics and Survival Outcome of Arsenic Related Bladder Cancer in Taiwan. Commentary
    181:2, p. 547 - 553 2009
  • International braz j urol : official journal of the Brazilian Society of Urology
    Villanueva Carlos, Difficult male urethral catheterization: a review of different approaches
    34:4, p. 401 - 11; discussion 412 2008
  • The Journal of urology
    Pisarev Vladimir M, VACCINATION OF PROSTATE CANCER PATIENTS WITH GENETICALLY MODIFIED ALLOGENEIC TUMOR CELL VACCINE INDUCES IgG RESPONSES TOWARD MULTIPLE PEPTIDE EPITOPES PREDICTED FROM COMMON PROSTATE TUMOR- ASSOCIATED AUTOANTIGENS
    179:4S, p. 230 - 230 2008
  • Clinical cancer research
    Sabichi Anita L., Phase III prevention trial of Fenretinide in patients with resected non-muscle-invasive bladder cancer
    14:1, p. 224 - 229 2008
  • International journal of cancer
    Carreon Tania, 'N-Acetyltransferases and the susceptibility to benzidine-induced bladder carcinogenesis' - Reply
    121:7, p. 1637 - 1639 2007
  • Cancer epidemiology, biomarkers & prevention
    Huang DALI, Quantitative fluorescence imaging analysis for cancer biomarker discovery : Application to β-catenin in archived prostate specimens
    16:7, p. 1371 - 1381 2007
  • The Journal of urology
    Hemstreet George P., 1717: Quantitative Fluorescence Imaging Analysis for Cancer Biomarker Discovery: Application to B-Catenin in Archived Prostate Specimens
    177:4S, p. 571 - 571 2007
  • Urology (Ridgewood, N.J.)
    Habuchi Tomonori, Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers
    66:6, p. 64 - 74 2005
  • Urologic oncology
    Lewis Tamra E, Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer
    23:6, p. 407 - 412 2005
  • Journal of clinical oncology
    Hemstreet G. P., Fluorescence imaging proteometry of thymosin β4 in single cells for detection of bladder transitional cell carcinoma
    23:16_suppl, p. 4745 - 4745 2005
  • Urology (Ridgewood, N.J.)
    Klingler Douglas W, Feasibility of robotic radical nephrectomy-initial results of single-institution pilot study
    65:6, p. 1086 - 1089 2005
  • The Journal of urology
    Lerner Seth P., 913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer
    173:4S, p. 246 - 247 2005
  • Cancer research (Chicago, Ill.)
    Jaggi Meena, E-Cadherin Phosphorylation by Protein Kinase D1/Protein Kinase Cμ is Associated with Altered Cellular Aggregation and Motility in Prostate Cancer
    65:2, p. 483 - 492 2005
  • Urology (Ridgewood, N.J.)
    Lokeshwar Vinata B, Bladder tumor markers beyond cytology : International consensus panel on bladder tumor markers
    66:6A, p. 35 - 63 2005
  • Frontiers in bioscience
    Hemstreet George P, Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine)
    9:1-3, p. 2671 - 2679 2004
  • Internal medicine news (Short Hills, N.J. 1995)
    Hemstreet George P, Is robotic-assisted surgery clearly superior for radical prostatectomy for prostate cancer?
    37:12, p. 12 2004
  • Urology
    Balaji K. C., Feasibility of robot-assisted totally intracorporeal laparoscopic ileal conduit urinary diversion: Initial results of a single institutional pilot study
    63:1, p. 51 - 55 2004
  • European urology supplements : official journal of the European Association of Urology
    Hemstreet George P, Biomarker profiles for individual risk assessment and prostate cancer prevention
    2:6, p. 177 - 177 2003
  • Anticancer research
    Hurst Robert E., Matrix-dependent Plasticity of the Malignant Phenotype of Bladder Cancer Cells
    23:4, p. 3119 - 3128 2003
  • The Journal of urology
    Wehbi Nizar K, Pan-cadherin as a high level phenotypic biomarker for prostate cancer
    167:5, p. 2215 - 2221 2002
  • BioTechniques
    Rao Jian Yu, Protein Expression Analysis Using Quantitative Fluorescence Image Analysis on Tissue Microarray Slides
    32:4, p. 924 - 932 2002
  • JNCI : Journal of the National Cancer Institute
    Hemstreet George, RESPONSE: Re: Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine
    93:19, p. 1492a - 1493 2001
  • JNCI : Journal of the National Cancer Institute
    Hemstreet George P., Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine
    93:6, p. 427 - 436 2001
  • Cancer
    Birckbichler Paul J., Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma
    89:2, p. 412 - 423 2000
  • Cancer detection and prevention
    Hemstreet G P, Abnormal G-actin content in single prostate cells as a biomarker of prostate cancer
    24:5, p. 464 - 472 2000
  • The Journal of urology
    Lianes P., Biomarker Study of Primary Nonmetastatic Versus Metastatic Invasive Bladder Cancer
    161:5, p. 1716 - 1717 1999
  • The Journal of urology
    Birckbichler Paul J., EXPRESSION OF TISSUE TRANSGLUTAMINASE IN HUMAN DIABETIC KIDNEY TISSUE SECTIONS, p. 84 1999
  • The Journal of urology
    Hemstreet George P., BIOMARKERS IN THE PREMALIGNANT FIELD PREDICT INDIVIDUAL CANCER RISK, p. 153 1999
  • The Journal of urology
    Hemstreet George P., EXPRESSION AND PROGNOSTIC VALUE OF CD44 ISOFORMS IN TRANSITIONAL CELL CARCINOMA OF RENAL PELVIS AND URETER, p. 808 - 809 1999
  • Molecular and cellular endocrinology
    Waliszewski Przemyslaw, Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells
    148:1, p. 55 - 65 1999
  • Urologic oncology
    Waliszewski Przemyslaw, Expression of sex steroid receptor genes and comodulation with retinoid signaling in normal human uroepithelial cells and bladder cancer cell lines
    3:5, p. 141 - 147 1997
  • Seminars in oncology
    Bane B L, Pathology and staging of bladder cancer
    23:5, p. 546 - 570 1996
  • The Journal of urology
    Mora L. B, Ancillary techniques in the followup of transitional cell carcinoma : A comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. Commentary
    156:1, p. 49 - 55 1996
  • Journal of immunotherapy (1997)
    Whitehead Robert P., A Phase II Trial of Continuous-Infusion Recombinant Interleukin-2 in Patients with Advanced Renal Cell Carcinoma
    18:2, p. 104 - 114 1995
  • Environmental and molecular mutagenesis
    Kusser Wolfgang C., p53 mutations in human bladder cancer
    24:3, p. 156 - 160 1994
  • Cancer
    Bonner Rebecca B., Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells
    72:8, p. 2461 - 2469 1993
  • Proceedings of the National Academy of Sciences - PNAS
    Rao Jian Yu, Alterations in Phenotypic Biochemical Markers in Bladder Epithelium During Tumorigenesis
    90:17, p. 8287 - 8291 1993
  • The Journal of urology
    Kuebler J. Philip, Treatment of Metastatic Renal Cell Carcinoma with Recombinant Interleukin-2 in Combination with Vinblastine or Lymphokine-Activated Killer Cells
    150:3, p. 814 - 820 1993
  • Journal of occupational medicine
    Bi WenFang, Field Molecular Epidemiology: Feasibility of Monitoring for the Malignant Bladder Cell Phenotype in a Benzidine-Exposed Occupational Cohort
    35:1, p. 20 - 27 1993
  • The Journal of urology
    Hemstreet George P., Identification of a High Risk Subgroup of Grade 1 Transitional Cell Carcinoma Using Image Analysis Based Deoxyribonucleic Acid Ploidy Analysis of Tumor Tissue
    146:6, p. 1525 - 1529 1991
  • The Journal of urology
    Moon Timothy D., Quantitative Fluorescence Image Analysis of Deoxyribonucleic Acid Ploidy in Urine From Normal Children
    145:6, p. 1236 - 1237 1991
  • Journal of occupational medicine
    Marsh Gary M., A Protocol for Bladder Cancer Screening and Medical Surveillance among High-Risk Groups: The Drake Health Registry Experience
    32:9, p. 881 - 886 1990
  • Journal of occupational medicine
    Hemstreet George P., Quantitative Fluorescence Image Analysis in Bladder Cancer Screening
    32:9, p. 822 - 828 1990
  • The American journal of surgery
    McGowan Patrick F., Early detection of colorectal cancer by quantitative fluorescence image analysis of exfoliated cells
    159:1, p. 172 - 177 1990
  • Hurst R. E, Molecular and cellular biological approaches and techniques in the detection of bladder cancer and enhanced risk for bladder cancer in high-risk groups 1990
  • International journal of cancer
    Hemstreet George P., DNA hyperploidy as a marker for biological response to bladder carcinogen exposure
    42:6, p. 817 - 820 1988
  • The Journal of urology
    Parry William L., Cancer Detection by Quantitative Fluorescence Image Analysis
    139:2, p. 270 - 274 1988
  • Toxicology and industrial health
    Pitha Jan V., Occupational Hydrocarbon Exposure and Renal Histopathology
    3:4, p. 491 - 506 1987
  • International journal of cancer
    Bass Rebecca A., DNA cytometry and cytology by quantitative fluorescence image analysis in symptomatic bladder cancer patients
    40:5, p. 698 - 705 1987
  • Gynecologic oncology
    Smith Jeffrey J., Automated quantitative fluorescent image analysis of cervical cytology
    28:3, p. 241 - 254 1987
  • The Journal of urology
    Hemstreet George P., 452 - Qfia in Defining Bladder Cancer Risk in High-Risk Cohorts and Management of Symptomatic Bladder Cancer Patients
    137:6, p. 216A - 216A 1987
  • The Journal of urology
    Hemstreet George P., 475 - Interleukin 2 (IL-2) in the Management of Patients with Renal Cell Carcinoma
    137:6, p. 222A - 222A 1987
  • Chest
    Gasbarra D., Automated Identification of Aneuploid Cells in Lung Cancer
    91:3, p. 3s - 4s 1987
  • Cancer
    Schulte Paul A., Risk factors for bladder cancer in a cohort exposed to aromatic amines
    58:9, p. 2156 - 2162 1986
  • Journal of occupational medicine
    Schulte Paul A., Optimal Management of Asymptomatic Workers at High Risk of Bladder Cancer
    28:1, p. 13 - 17 1986
  • International journal of cancer
    Hemstreet George P., Quantitative fluorescence measurements of ao‐stained normal and malignant bladder cells
    31:5, p. 577 - 585 1983
  • The Journal of urology
    Smalley R.V., A Phase II Evaluation of a 3-Drug Combination of Cyclophosphamide, Doxorubicin and 5-Fluorouracil and of 5-Fluorouracil in Patients with Advanced Bladder Carcinoma or Stage D Prostatic Carcinoma
    125:2, p. 191 - 195 1981
  • International journal of cancer
    Hemstreet George P., Comparison of steroid receptor levels in renal‐cell carcinoma and autologous normal kidney
    26:6, p. 769 - 775 1980
  • Urology (Ridgewood, N.J.)
    Griggs W.Phillips, Pathologic and immunologic considerations in malakoplakia
    16:6, p. 638 - 645 1980
  • Urology (Ridgewood, N.J.)
    Older Robert A., Suspicious appearance of simple cyst caused by technical artifact
    9:4, p. 466 - 468 1977
  • Urology (Ridgewood, N.J.)
    Sink James D., Technique to assure urinary drainage through nephrostoiviy tube
    9:2, p. 185 - 185 1977

Awards

  • Unemed New Invention Contributor 2009
    UNMC
  • Citation for Meritorious Services to the Oklahoma City Bombing Victims
    American Medical Association
  • Biological Markers in Urinary Toxicology
    National Research Council, ed. Washington, DC
  • Honorable Visiting Professor
    Department of Urological Oncology, Cancer Institute (Hospital)
    Chinese Academy of Medical Sciences, Beijing, China
  • George Lynn Cross Research Professorship
    The University of Oklahoma
  • Visiting Professor
    Department of Urology, Chongging Cancer Institute, Beijing, China
    Chinese Academy of Preventive Medicine
  • Young Investigators Award
    NIH